Лаборатория биокатализа

Отдел пептидно-белковых технологий

Руководитель: Габибов Александр Габибович, академик
gabibov@mx.ibch.ru+7(495)727-38-60

биокатализ, каталитические антитела, аутоиммунные заболевания, протеасома, рекомбинантные белки, цитокины, интерфероны, гормон роста, протеолиз, пептидные ингибиторы

Лаборатория биокатализа была основана в ИБХ в 1997 г. В лаборатории развивается два основных проекта, которые идейно вышли из пионерских работ заведующего лабораторией профессора Габибова.

Первая группа под руководством Ивана Смирнова продолжает заниматься классической «абзимологией» (абзимы - антитела, обладающие свойствами ферментов), но уже на качественно новом уровне. Здесь ищется баланс между комбинаторными методами и рациональным дизайном с целью создания белков с заранее заданными свойствами de novo. В последнее время группа активно осваивает микрофлюидные технологии для осуществления многопараметрического скрининга клонов биокатализаторов и вообще клеток.

Вторая группа под руководством Алексея Белогурова изучает молекулярные основы аутоиммунных процессов с уклоном в аутоиммунную нейродегенерацию. В основном, на повестке дня стоит хроническое демиелинизирующее заболевание центральной нервной системы — рассеянный склероз, и в последнее время и нейродегенерация периферической нервной системы — синдром Гийена-Барре. В лаборатории разрабатываются скрининговые технологии, например дрожжевой, фаговый и лентивирусный дисплеи (в этих работах участвует группа Татьяны Бобик).

Ранее в лаборатории были достигнуты значительные успехи в области биотехнологии – экспрессии белков, например, факторов крови, антител в прокариотических системах и в клеточной линии СНО. Огромный вклад в эти исследования внесла профессор Наталья Пономаренко.

Лаборатория имеет широкий круг партнеров, как в Институте, так и за его пределами. Совместно с Лабораторией протеомики изучается рассеянный склероз и синдром Гийена-Барре, ведется работа над созданием иммунотоксинов с Лабораторией инженерии белка и Лабораторией молекулярной иммунологии, ведется изучение ионных каналов в аутореактивных лимфоцитах вместе с Группой молекулярных инструментов для нейробиологии.

Кроме того, Лаборатория сотрудничает с Европейской молекулярно-биологической лабораторией в Гамбурге, с НИИ физико-химической медицины, Центром нанотехнологий РАН, Институтом химической биологии и фундаментальной медицины СО РАН, НТЦ «БиоКлиникум» и НИИ физико-химической биологии им. А.Н. Белозерского МГУ. Лаборатория дружит и с несколькими выдающимися личностями: нобелевскими лауреатами Аароном Чехановером и Сиднеем Альтманом, бывшим президентом Института Скриппса и отцом современной абзимологии Ричардом Лернером и многими другими.

  • Общие проблемы биокатализа, структурно-функциональные взаимоотношения, определяющие каталитическую эффективность биокатализатора, искусственные ферменты, каталитические антитела-абзимы.
  • Проблемы индукции каталитической активности молекул суперсемейства иммуноглобулинов.
  • Антиидиотипические антитела как модель, обеспечивающая передачу функциональной активности белковой молекулы.
  • Проблемы природной каталитической активности и корреляция каталитической активности антител по отношению к аутоантигенам с глубиной развития патологических процессов.
  • Молекулярные основы аутоиммунных заболеваний. Роль протеасомы в аутоимунных патологиях ЦНС. Животные модели аутоиммунных процессов. Проблемы направленного элиминирования патологических В-лимфоцитов.
  • Создание каталитических вакцин, способных разрушать низкомолекулярные токсины, фосфорорганические яды и белки оболочки вирусов, в частности ВИЧ.
  • Каталитические антитела к биополимерам.
  • Антитела-протеазы и ДНКазы. Проблемы цитотоксичности аутоантител и механизмы апоптоза (совместно с Лабораторией иммунологии рака Института биологии гена РАН).
  • Протеазы, индуцируемые при аутоиммунных процессах. Протеазы патогенов (совместно с лабораторией химии ферментов ИБХ РАН). Комбинаторные подходы (в частности фаговый дисплей) для поиска эффективных субстратов протеаз. ДНК-топоизомеразы и механизмы взаимодействия с противораковыми препаратами. Механизмы действия эстераз.
  • Биотехнологические исследования (совместно с лабораторией биотехнологии ИБХ РАН): создание лекарственных препаратов на основе рекомбинантных белков, экспрессируемых в про- и эукариотических системах. Получение пролонгированных лекарственных средств с помощью полисиалирования, получение комбинированных ДНК-белковых вакцин.
  • Высказано предположение о наличии «природной каталитической активности» антител по отношению к аутоантигенам при патологических процессах в организме человека и у модельных животных.
  • Открыты природные ДНК-абзимы. Показаны цитотоксические эффекты этих антител. Установлен молекулярный механизм их действия на уровне 3D. Показано, что каталитические антитела могут быть получены как антиидиотипические антитела к ферментам.
  • Получена искусственная протеаза и ацетилхолинэстераза (совместно с технологическим университетом —  г. Компьень, Франция). Продемонстрировано ее специфическое взаимодействие с аналогами фосфорорганических отравляющих веществ.
  • Установлен механизм действия, получены кристаллы и разрешена трехмерная структура первого каталитического антитела, взаимодействующего с аналогами фосфорорганических отравляющих веществ. Показана ДНК-гидролизующая активность этого антитела и установлен механизм его действия.
  • Найден способ получения эпитоп-специфические каталитических антител-протеаз.
  • Получены антитела, специфически разрезающие поверхностный белок оболочки ВИЧ, gp120. Обнаружена сайт-специфическая деградация основного белка миелина под действием аутоантител, выделенных из сывороток крови больных рассеянным склерозом и модельных животных, развивающих ЕАЕ (экспериментальный аутоиммунный энцефаломиелит) и продемонстрирован диагностический и прогностический потенциал этого эффекта.
  • Установлена роль убиквитин-независимого протеолиза основного белка миелина в развитии нейродегенеративных патологий ЦНС.
  • Впервые предложен метод оптической детекции ДНК-топоизомеразной реакции. Установлен кинетический механизм ДНК-топоизомераз.
  • С помощью методов предстационарной кинетики установлен механизм действия летального фактора сибирской язвы.
  • Совместно с лабораторией биотехнологии ИБХ РАН получен отечественный препарат «Растан» (рекомбинантный гормон роста человека), колониестимулирующий фактор, рекомбинантный фактор свертывания крови VII.
Ф.И.О.ДолжностьКонтакты
Габибов Александр Габибович, академикрук. подр.gabibov@mx.ibch.ru+7(495)727-38-60
Северин Евгений Сергеевич, чл.-корр. РАНв.н.с.e.severin@mail.ru
Тоневицкий Александр Григорьевич, чл.-корр. РАНв.н.с.tonevitsky@mail.ru
Пономаренко Наталья Александровна, д. б. н.в.н.с.+7(495)4298269
Донцова Ольга Анатольевна, академикс.н.с.olga.a.dontsova@gmail.com
Белогуров Алексей Анатольевич, к. х. н.с.н.с.belogurov@mx.ibch.ru+7(495)7273860
Смирнов Иван Витальевич, к. х. н.с.н.с.ivansmr@inbox.ru+7(495)000-00-00
Колесников Александр Владимирович, к. б. н.с.н.с.+7(495)2255309
Кузина Екатерина Сергеевнан.с.kat.kuzina@gmail.com
Захарова Мария Юрьевна, к. б. н.н.с.zakharova@ibch.ru+7(495)429-82-69
Воробьев Иван Иванович, к. х. н.н.с.ptichman@gmail.com+7(495)429-82-69
Дронина Мария Алексеевна, к. б. н.н.с.mdronina@mail.ru
Дубилей Светлана Алексеевна, к. б. н.н.с.+7(495)225-53-09
Дурова Оксана Михайловнан.с.
Кнорре Вера Дмитриевна, к. х. н.н.с.vera.knorre@gmail.com+7(495)7273860
Козырь Арина Владимировна, к. б. н.н.с.+7(495)429-82-69
Степанова Анастасия Валерьевнан.с.avkaznacheeva@gmail.com
Степанов Алексей Вячеславович, к. б. н.н.с.stepanov.aleksei.v@gmail.com
Ломакин Яков Анатольевич, к. б. н.н.с.yasha.l@bk.ru
Орлова Надежда , к. б. н.н.с.nobiol@gmail.com
Илюшин Денис Григорьевичн.с.IlyushinDenis@gmail.com
Бобик Татьяна Владимировна, к. х. н.н.с.bobik_tanya@mail.ru
Каминская Алена Николаевнан.с.
Костин Никита Николаевичасп.nkostin1@gmail.com
Кудряева Анна Анатольевнаасп.anna.kudriaeva@gmail.com
Мамедов Азад Энверовичинженерbioaz12@gmail.com

Избранные публикации

  1. Smirnov I.V., Golovin A.V., Chatziefthimiou S.D., Stepanova A.V., Peng Y., Zolotareva O.I., Belogurov A.A. Jr, Kurkova I.N., Ponomarenko N.A., Wilmanns M., Blackburn G.M., Gabibov A.G., Lerner R.A. (2016). Robotic QM/MM-driven maturation of antibody combining sites. Sci Adv 2 (10), e1501695 [+]

    In vitro selection of antibodies from large repertoires of immunoglobulin (Ig) combining sites using combinatorial libraries is a powerful tool, with great potential for generating in vivo scavengers for toxins. However, addition of a maturation function is necessary to enable these selected antibodies to more closely mimic the full mammalian immune response. We approached this goal using quantum mechanics/molecular mechanics (QM/MM) calculations to achieve maturation in silico. We preselected A17, an Ig template, from a naïve library for its ability to disarm a toxic pesticide related to organophosphorus nerve agents. Virtual screening of 167,538 robotically generated mutants identified an optimum single point mutation, which experimentally boosted wild-type Ig scavenger performance by 170-fold. We validated the QM/MM predictions via kinetic analysis and crystal structures of mutant apo-A17 and covalently modified Ig, thereby identifying the displacement of one water molecule by an arginine as delivering this catalysis.

    ID:1605
  2. Belogurov A., Zakharov K., Lomakin Y., Surkov K., Avtushenko S., Kruglyakov P., Smirnov I., Makshakov G., Lockshin C., Gregoriadis G., Genkin D., Gabibov A., Evdoshenko E. (2016). CD206-Targeted Liposomal Myelin Basic Protein Peptides in Patients with Multiple Sclerosis Resistant to First-Line Disease-Modifying Therapies: A First-in-Human, Proof-of-Concept Dose-Escalation Study. Neurotherapeutics , [+]

    Previously, we showed that CD206-targeted liposomal delivery of co-encapsulated immunodominant myelin basic protein (MBP) sequences MBP46-62, MBP124-139 and MBP147-170 (Xemys) suppressed experimental autoimmune encephalomyelitis in dark Agouti rats. The objective of this study was to assess the safety of Xemys in the treatment of patients with relapsing-remitting multiple sclerosis (MS) and secondary progressive MS, who failed to achieve a sustained response to first-line disease-modifying therapies. In this phase I, open-label, dose-escalating, proof-of-concept study, 20 patients with relapsing-remitting or secondary progressive MS received weekly subcutaneously injections with ascending doses of Xemys up to a total dose of 2.675 mg. Clinical examinations, including Expanded Disability Status Scale score, magnetic resonance imaging results, and serum cytokine concentrations, were assessed before the first injection and for up to 17 weeks after the final injection. Xemys was safe and well tolerated when administered for 6 weeks to a maximum single dose of 900 μg. Expanded Disability Status Scale scores and numbers of T2-weighted and new gadolinium-enhancing lesions on magnetic resonance imaging were statistically unchanged at study exit compared with baseline; nonetheless, the increase of number of active gadolinium-enhancing lesions on weeks 7 and 10 in comparison with baseline was statistically significant. During treatment, the serum concentrations of the cytokines monocyte chemoattractant protein-1, macrophage inflammatory protein-1β, and interleukin-7 decreased, whereas the level of tumor necrosis factor-α increased. These results provide evidence for the further development of Xemys as an antigen-specific, disease-modifying therapy for patients with MS.

    ID:1535
  3. Ziganshin R.H., Ivanova O.M., Lomakin Y.A., Belogurov A.A. Jr, Kovalchuk S.I., Azarkin I.V., Arapidi G.P., Anikanov N.A., Shender V.O., Piradov M.A., Suponeva N.A., Vorobyeva A.A., Gabibov A.G., Ivanov V.T., Govorun V.M. (2016). The pathogenesis of demyelinating form of Guillain-Barre syndrome: proteo-peptidomic and immunological profiling of physiological fluids. Mol. Cell Proteomics , [+]

    Acute inflammatory demyelinating polyneuropathy (AIDP) - the main form of Guillain-Barre syndrome (GBS) - is a rare and severe disorder of the peripheral nervous system (PNS) with an unknown etiology. One of the hallmarks of the AIDP pathogenesis is a significantly elevated cerebrospinal fluid (CSF) protein level. In this paper CSF peptidome and proteome in AIDP were analyzed and compared with multiple sclerosis (MS) and control patients. A total protein concentration increase was shown to be due to even changes in all proteins rather than some specific response, supporting the hypothesis of protein leakage from blood through the blood-nerve barrier. The elevated CSF protein level in AIDP was complemented by activization of protein degradation and much higher peptidome diversity. Due to the studies of the acute motor axonal form, GBS as a whole is thought to be associated with autoimmune response against neurospecific molecules. Thus, in AIDP, autoantibodies against cell adhesion (CAM) proteins localized at Ranvier's nodes were suggested as possible targets in AIDP. Indeed, AIDP CSF peptidome analysis revealed CAM proteins degradation, however no reliable dependence on the corresponding autoantibodies levels was found. Proteome analysis revealed overrepresentation of Gene Ontology groups related to responses to bacteria and virus infections, which were earlier suggested as possible AIDP triggers. Immunoglobulin blood serum analysis against most common neuronal viruses did not reveal any specific pathogen; however AIDP patients were more immunopositive in average and often had polyinfections. Cytokine analysis of both AIDP CSF and blood did not show a systemic adaptive immune response or general inflammation, while innate immunity cytokines were upregulated. To supplement the widely-accepted though still unproven autoimmunity-based AIDP mechanism we propose a hypothesis of the primary PNS damaging initiated as an innate immunity-associated local inflammation following neurotropic viruses egress, while the autoantibody production might be an optional complementary secondary process.

    ID:1523
  4. Stepanov A., Belyy A., Kasheverov I., Rybinets A., Dronina M., Dyachenko I., Murashev A., Knorre V., Sakharov D., Ponomarenko N., Tsetlin V., Tonevitsky A., Deyev S., Belogurov A., Gabibov A. (2016). Development of a recombinant immunotoxin for the immunotherapy of autoreactive lymphocytes expressing MOG-specific BCRs. Biotechnol. Lett. , [+]

    Myelin oligodendrocyte glycoprotein (MOG) is one of the major autoantigens in multiple sclerosis (MS), therefore selective depletion of autoreactive lymphocytes exposing MOG-specific B cell receptors (BCRs) would be beneficial in terms of MS treatment.

    ID:1524
  5. Belogurov A., Kuzina E., Kudriaeva A., Kononikhin A., Kovalchuk S., Surina Y., Smirnov I., Lomakin Y., Bacheva A., Stepanov A., Karpova Y., Lyupina Y., Kharybin O., Melamed D., Ponomarenko N., Sharova N., Nikolaev E., Gabibov A. (2015). Ubiquitin-independent proteosomal degradation of myelin basic protein contributes to development of neurodegenerative autoimmunity. FASEB J. , [+]

    Recent findings indicate that the ubiquitin-proteasome system is involved in the pathogenesis of cancer as well as autoimmune and several neurodegenerative diseases, and is thus a target for novel therapeutics. One disease that is related to aberrant protein degradation is multiple sclerosis, an autoimmune disorder involving the processing and presentation of myelin autoantigens that leads to the destruction of axons. Here, we show that brain-derived proteasomes from SJL mice with experimental autoimmune encephalomyelitis (EAE) in an ubiquitin-independent manner generate significantly increased amounts of myelin basic protein peptides that induces cytotoxic lymphocytes to target mature oligodendrocytes ex vivo. Ten times enhanced release of immunogenic peptides by cerebral proteasomes from EAE-SJL mice is caused by a dramatic shift in the balance between constitutive and β1i(high) immunoproteasomes in the CNS of SJL mice with EAE. We found that during EAE, β1i is increased in resident CNS cells, whereas β5i is imported by infiltrating lymphocytes through the blood-brain barrier. Peptidyl epoxyketone specifically inhibits brain-derived β1i(high) immunoproteasomes in vitro (kobs/[I] = 240 M(-1)s(-1)), and at a dose of 0.5 mg/kg, it ameliorates ongoing EAE in vivo. Therefore, our findings provide novel insights into myelin metabolism in pathophysiologic conditions and reveal that the β1i subunit of the immunoproteasome is a potential target to treat autoimmune neurologic diseases.-Belogurov Jr., A., Kuzina, E., Kudriaeva, A., Kononikhin, A., Kovalchuk, S., Surina, Y., Smirnov, I., Lomakin, Y., Bacheva, A., Stepanov, A., Karpova, Y., Lyupina, Y., Kharybin, O., Melamed, D., Ponomarenko, N., Sharova, N., Nikolaev, E., Gabibov, A. Ubiquitin-independent proteosomal degradation of myelin basic protein contributes to development of neurodegenerative autoimmunity.

    ID:1244
  6. Belogurov A., Kudriaeva A., Kuzina E., Smirnov I., Bobik T., Ponomarenko N., KravtsovaIvantsiv Y., Ciechanover A., Gabibov A. (2014). Multiple Sclerosis Autoantigen Myelin Basic Protein Escapes Control by Ubiquitination During Proteasomal Degradation. J. Biol. Chem. , [+]

    The vast majority of cellular proteins are degraded by the 26S proteasome after their ubiquitination. Here, we report that the major component of the myelin multilayered membrane sheath, myelin basic protein (MBP), is hydrolyzed by the 26S proteasome in a ubiquitin-independent manner both in vitro and in mammalian cells. As a proteasomal substrate, MBP reveals a distinct and physiologically relevant concentration range for ubiquitin-independent proteolysis. Enzymatic deimination prevents hydrolysis of MBP by the proteasome, suggesting that an abnormally basic charge contributes to its susceptibility towards proteasome-mediated degradation. To our knowledge, our data reveal the first case of a pathophysiologically important autoantigen as a ubiquitin-independent substrate of the 26S proteasome.

    ID:1013
  7. Ponomarenko N., Chatziefthimiou S.D., Kurkova I., Mokrushina Y., Stepanova A., Smirnov I., Avakyan M., Bobik T., Mamedov A., Mitkevich V., Belogurov A., Fedorova O.S., Dubina M., Golovin A., Lamzin V., Friboulet A., Makarov A.A., Wilmanns M., Gabibov A. (2014). Role of κ→λ light-chain constant-domain switch in the structure and functionality of A17 reactibody. Acta Crystallogr. D Biol. Crystallogr. 70 (Pt 3), 708–19 [+]

    The engineering of catalytic function in antibodies requires precise information on their structure. Here, results are presented that show how the antibody domain structure affects its functionality. The previously designed organophosphate-metabolizing reactibody A17 has been re-engineered by replacing its constant κ light chain by the λ chain (A17λ), and the X-ray structure of A17λ has been determined at 1.95 Å resolution. It was found that compared with A17κ the active centre of A17λ is displaced, stabilized and made more rigid owing to interdomain interactions involving the CDR loops from the VL and VH domains. These VL/VH domains also have lower mobility, as deduced from the atomic displacement parameters of the crystal structure. The antibody elbow angle is decreased to 126° compared with 138° in A17κ. These structural differences account for the subtle changes in catalytic efficiency and thermodynamic parameters determined with two organophosphate ligands, as well as in the affinity for peptide substrates selected from a combinatorial cyclic peptide library, between the A17κ and A17λ variants. The data presented will be of interest and relevance to researchers dealing with the design of antibodies with tailor-made functions.

    ID:1245
  8. Lomakin Y.A., Zakharova M.Y., Stepanov A.V., Dronina M.A., Smirnov I.V., Bobik T.V., Pyrkov A.Y., Tikunova N.V., Sharanova S.N., Boitsov V.M., Vyazmin S.Y., Kabilov M.R., Tupikin A.E., Krasnov A.N., Bykova N.A., Medvedeva Y.A., Fridman M.V., Favorov A.V., Ponomarenko N.A., Dubina M.V., Boyko A.N., Vlassov V.V., Belogurov A.A. Jr, Gabibov A.G. (2014). Heavy-light chain interrelations of MS-associated immunoglobulins probed by deep sequencing and rational variation. Mol. Immunol. , [+]

    The mechanisms triggering most of autoimmune diseases are still obscure. Autoreactive B cells play a crucial role in the development of such pathologies and, in particular, production of autoantibodies of different specificities. The combination of deep-sequencing technology with functional studies of antibodies selected from highly representative immunoglobulin combinatorial libraries may provide unique information on specific features in the repertoires of autoreactive B cells. Here, we have analyzed cross-combinations of the variable regions of human immunoglobulins against the myelin basic protein (MBP) previously selected from a multiple sclerosis (MS)-related scFv phage-display library. On the other hand, we have performed deep sequencing of the sublibraries of scFvs against MBP, Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1), and myelin oligodendrocyte glycoprotein (MOG). Bioinformatics analysis of sequencing data and surface plasmon resonance (SPR) studies have shown that it is the variable fragments of antibody heavy chains that mainly determine both the affinity of antibodies to the parent autoantigen and their cross-reactivity. It is suggested that LMP1-cross-reactive anti-myelin autoantibodies contain heavy chains encoded by certain germline gene segments, which may be a hallmark of the EBV-specific B cell subpopulation involved in MS triggering.

    ID:1009
  9. Kuzina E., Kudriaeva A., Smirnov I., Dubina M.V., Gabibov A., Belogurov A. (2014). Glatiramer Acetate and Nanny Proteins Restrict Access of the Multiple Sclerosis Autoantigen Myelin Basic Protein to the 26S Proteasome. Biomed Res Int 2014, 926394 [+]

    We recently showed that myelin basic protein (MBP) is hydrolyzed by 26S proteasome without ubiquitination. The previously suggested concept of charge-mediated interaction between MBP and the proteasome led us to attempt to compensate or mimic its positive charge to inhibit proteasomal degradation. We demonstrated that negatively charged actin and calmodulin (CaM), as well as basic histone H1.3, inhibit MBP hydrolysis by competing with the proteasome and MBP, respectively, for binding their counterpart. Interestingly, glatiramer acetate (GA), which is used to treat multiple sclerosis (MS) and is structurally similar to MBP, inhibits intracellular and in vitro proteasome-mediated MBP degradation. Therefore, the data reported in this study may be important for myelin biogenesis in both the normal state and pathophysiological conditions.

    ID:1089
  10. Gasparian M.E., Bobik T.V., Kim Y.V., Ponomarenko N.A., Dolgikh D.A., Gabibov A.G., Kirpichnikov M.P. (2013). Heterogeneous catalysis on the phage surface: Display of active human enteropeptidase. Biochimie 95 (11), 2076–81 [+]
    ID:924
  11. Ilyushin D.G., Smirnov I.V., Belogurov A.A. Jr, Dyachenko I.A., Zharmukhamedova T.I.u., Novozhilova T.I., Bychikhin E.A., Serebryakova M.V., Kharybin O.N., Murashev A.N., Anikienko K.A., Nikolaev E.N., Ponomarenko N.A., Genkin D.D., Blackburn G.M., Masson P., Gabibov A.G. (2013). Chemical polysialylation of human recombinant butyrylcholinesterase delivers a long-acting bioscavenger for nerve agents in vivo. Proc. Natl. Acad. Sci. U.S.A. 110 (4), 1243–8 [+]

    The creation of effective bioscavengers as a pretreatment for exposure to nerve agents is a challenging medical objective. We report a recombinant method using chemical polysialylation to generate bioscavengers stable in the bloodstream. Development of a CHO-based expression system using genes encoding human butyrylcholinesterase and a proline-rich peptide under elongation factor promoter control resulted in self-assembling, active enzyme multimers. Polysialylation gives bioscavengers with enhanced pharmacokinetics which protect mice against 4.2 LD(50) of S-(2-(diethylamino)ethyl) O-isobutyl methanephosphonothioate without perturbation of long-term behavior.

    ID:1246
  12. Belogurov A.A. Jr, Stepanov A.V., Smirnov I.V., Melamed D., Bacon A., Mamedov A.E., Boitsov V.M., Sashchenko L.P., Ponomarenko N.A., Sharanova S.N., Boyko A.N., Dubina M.V., Friboulet A., Genkin D.D., Gabibov A.G. (2012). Liposome-encapsulated peptides protect against experimental allergic encephalitis. FASEB J. , [+]

    Multiple sclerosis (MS) is a severe inflammatory and neurodegenerative disease with an autoimmune background. Despite the variety of therapeutics available against MS, the development of novel approaches to its treatment is of high importance in modern pharmaceutics. In this study, experimental autoimmune encephalomyelitis (EAE) in Dark Agouti rats has been treated with immunodominant peptides of the myelin basic protein (MBP) encapsulated in mannosylated small unilamellar vesicles. The results show that liposome-encapsulated MBP(46-62) is the most effective in reducing maximal disease score during the first attack, while MBP(124-139) and MBP(147-170) can completely prevent the development of the exacerbation stage. Both mannosylation of liposomes and encapsulation of peptides are critical for the therapeutic effect, since neither naked peptides nor nonmannosylated liposomes, loaded or empty, have proved effective. The liposome-mediated synergistic effect of the mixture of 3 MBP peptides significantly suppresses the progression of protracted EAE, with the median cumulative disease score being reduced from 22 to 14 points, compared to the placebo group; prevents the production of circulating autoantibodies; down-regulates the synthesis of Th1 cytokines; and induces the production of brain-derived neurotrophic factor in the central nervous system. Thus, the proposed formulation ameliorates EAE, providing for a less severe first attack and rapid recovery from exacerbation, and offers a promising therapeutic modality in MS treatment.-Belogurov, A. A., Jr., Stepanov, A. V., Smirnov, I. V., Melamed, D., Bacon, A., Mamedov, A. E., Boitsov, V. M., Sashchenko, L. P., Ponomarenko, N. A., Sharanova, S. N., Boyko, A. N., Dubina, M. V., Friboulet, A., Genkin, D. D., Gabibov, A. G. Liposome-encapsulated peptides protect against experimental allergic encephalitis.

    ID:736
  13. Belogurov A., Smirnov I., Ponomarenko N., Gabibov A. (2012). Antibody-antigen pair probed by combinatorial approach and rational design: bringing together structural insights, directed evolution, and novel functionality. FEBS Lett. 586 (18), 2966–73 [+]

    The unique hypervariability of the immunoglobulin (Ig) superfamily provides a means to create both binding and catalytic antibodies with almost any desired specificity and activity. The diversity of antigens and concept of adaptive response suggest that it is possible to find an antigen pair to any raised Ig. In the current review we discuss combinatorial approaches, which makes it possible to obtain an antibody with predefined properties, followed by 3D structure-based rational design to enhance or dramatically change its characteristics. A similar strategy, but applied to the second partner of the antibody-antigen pair, may result in selection of complementary substrates to the chosen Ig. Finally, 2D screening may be performed solving the "Chicken and Egg" problem when neither antibody nor antigen is known.

    ID:748
  14. Gabibov A.G., Belogurov A.A. Jr, Lomakin Y.A., Zakharova M.Y., Avakyan M.E., Dubrovskaya V.V., Smirnov I.V., Ivanov A.S., Molnar A.A., Gurtsevitch V.E., Diduk S.V., Smirnova K.V., Avalle B., Sharanova S.N., Tramontano A., Friboulet A., Boyko A.N., Ponomarenko N.A., Tikunova N.V. (2011). Combinatorial antibody library from multiple sclerosis patients reveals antibodies that cross-react with myelin basic protein and EBV antigen. FASEB J. 25 (12), 4211–21 [+]

    Multiple sclerosis (MS) is a widespread neurodegenerative autoimmune disease with unknown etiology. It is increasingly evident that, together with pathogenic T cells, autoreactive B cells are among the major players in MS development. The analysis of myelin neuroantigen-specific antibody repertoires and their possible cross-reactivity against environmental antigens, including viral proteins, could shed light on the mechanism of MS induction and progression. A phage display library of single-chain variable fragments (scFvs) was constructed from blood lymphocytes of patients with MS as a potential source of representative MS autoantibodies. Structural alignment of 13 clones selected toward myelin basic protein (MBP), one of the major myelin antigens, showed high homology within variable regions with cerebrospinal fluid MS-associated antibodies as well as with antibodies toward Epstein-Barr latent membrane protein 1 (LMP1). Three scFv clones showed pronounced specificity to MBP fragments 65-92 and 130-156, similar to the serum MS antibodies. One of these clones, designated E2, in both scFv and full-size human antibody constructs, was shown to react with both MBP and LMP1 proteins in vitro, suggesting natural cross-reactivity. Thus, antibodies induced against LMP1 during Epstein-Barr virus infection might act as inflammatory trigger by reacting with MBP, suggesting molecular mimicry in the mechanism of MS pathogenesis.

    ID:718
  15. Stepanov A.V., Belogurov A.A. Jr, Ponomarenko N.A., Stremovskiy O.A., Kozlov L.V., Bichucher A.M., Dmitriev S.E., Smirnov I.V., Shamborant O.G., Balabashin D.S., Sashchenko L.P., Tonevitsky A.G., Friboulet A., Gabibov A.G., Deyev S.M. (2011). Design of targeted B cell killing agents. PLoS ONE 6 (6), e20991 [+]

    B cells play an important role in the pathogenesis of both systemic and organ-specific autoimmune diseases. Autoreactive B cells not only produce autoantibodies, but also are capable to efficiently present specific autoantigens to T cells. Furthermore, B cells can secrete proinflammatory cytokines and amplify the vicious process of self-destruction. B cell-directed therapy is a potentially important approach for treatment of various autoimmune diseases. The depletion of B cells by anti-CD20/19 monoclonal antibody Retuximab® used in autoimmune diseases therapy leads to systemic side effects and should be significantly improved. In this study we designed a repertoire of genetically engineered B cell killers that specifically affected one kind of cells carrying a respective B cell receptor. We constructed immunotoxins (ITs), fused with c-myc epitope as a model targeting sequence, based on barnase, Pseudomonas toxin, Shiga-like toxin E.coli and Fc domain of human antibody IgGγ1. C-MYC hybridoma cell line producing anti-c-myc IgG was chosen as a model for targeted cell depletion. C-myc sequence fused with toxins provided addressed delivery of the toxic agent to the target cells. We demonstrated functional activity of designed ITs in vitro and showed recognition of the fusion molecules by antibodies produced by targeted hybridoma. To study specificity of the proposed B cells killing molecules, we tested a set of created ITs ex vivo, using C-MYC and irrelevant hybridoma cell lines. Pseudomonas-containing IT showed one of the highest cytotoxic effects on the model cells, however, possessed promiscuous specificity. Shiga-like toxin construct demonstrated mild both cytotoxicity and specificity. Barnase and Fc-containing ITs revealed excellent balance between their legibility and toxic properties. Moreover, barnase and Fc molecules fused with c-myc epitope were able to selectively deplete c-myc-specific B cells and decrease production of anti-c-myc antibodies in culture of native splenocytes, suggesting their highest therapeutic potential as targeted B cell killing agents.

    ID:719
  16. Belogurov A., Kozyr A., Ponomarenko N., Gabibov A. (2009). Catalytic antibodies: balancing between Dr. Jekyll and Mr. Hyde. Bioessays 31 (11), 1161–71 [+]

    The immunoglobulin molecule is a perfect template for the de novo generation of biocatalytic functions. Catalytic antibodies, or abzymes, obtained by the structural mimicking of enzyme active sites have been shown to catalyze numerous chemical reactions. Natural enzyme analogs for some of these reactions have not yet been found or possibly do not exist at all. Nowadays, the dramatic breakthrough in antibody engineering and expression technologies has promoted a considerable expansion of immunoglobulin's medical applications and is offering abzymes a unique chance to become a promising source of high-precision "catalytic vaccines." At the same time, the discovery of natural abzymes on the background of autoimmune disease revealed their beneficial and pathogenic roles in the disease progression. Thus, the conflicting Dr. Jekyll and Mr. Hyde protective and destructive essences of catalytic antibodies should be carefully considered in the development of therapeutic abzyme applications.

    ID:721
  17. Belogurov A.A. Jr, Zargarova T.A., Turobov V.I., Novikova N.I., Favorova O.O., Ponomarenko N.A., Gabibov A.G. (2009). Suppression of ongoing experimental allergic encephalomyelitis in DA rats by novel peptide drug, structural part of human myelin basic protein 46-62. Autoimmunity 42 (4), 362–4 [+]

    Previously, we demonstrated that autoantibodies (AAb) in multiple sclerosis (MS) reveal site-specific binding and cleavage toward myelin basic protein (MBP) epitope library. We have found several fragments of MBP immunodominant in terms of AAb binding. Here, we applied these peptides to DA rats with induced protracted relapsing experimental allergic encephalomyelitis (EAE) most closely related to MS. DA rats with EAE induced by syngenic spinal cord homogenate in complete Freund's adjuvant were treated by nasal route with human MBP 46-62, 81-102, 124-139, 147-170, and Copaxone. MBP 124-139 and 147-170 displayed only mild therapeutic effects but MBP 46-62 significantly reduced EAE, reflected by lower clinical scores and shorter EAE duration compared to controls.

    ID:720
  18. Belogurov A.A. Jr, Kurkova I.N., Friboulet A., Thomas D., Misikov V.K., Zakharova M.Y., Suchkov S.V., Kotov S.V., Alehin A.I., Avalle B., Souslova E.A., Morse H.C. 3rd, Gabibov A.G., Ponomarenko N.A. (2008). Recognition and degradation of myelin basic protein peptides by serum autoantibodies: novel biomarker for multiple sclerosis. J. Immunol. 180 (2), 1258–67 [+]

    The pathologic role of autoantibodies in autoimmune disease is widely accepted. Recently, we reported that anti-myelin basic protein (MBP) serum Abs from multiple sclerosis (MS) patients exhibit proteolytic activity toward the autoantigen. The aim of this study is to determine MBP epitopes specific for the autoantibodies in MS and compare these data with those from other neuronal disorders (OND), leading to the generation of new diagnostic and prognostic criteria. We constructed a MBP-derived recombinant "epitope library" covering the entire molecule. We used ELISA and PAGE/surface-enhanced laser desorption/ionization mass spectroscopy assays to define the epitope binding/cleaving activities of autoantibodies isolated from the sera of 26 MS patients, 22 OND patients, and 11 healthy individuals. The levels of autoantibodies to MBP fragments 48-70 and 85-170 as well as to whole MBP and myelin oligodendrocyte glycoprotein molecules were significantly higher in the sera of MS patients than in those of healthy donors. In contrast, selective reactivity to the two MBP fragments 43-68 and 146-170 distinguished the OND and MS patients. Patients with MS (77% of progressive and 85% of relapsing-remitting) but only 9% of patients with OND and no healthy donors were positive for catalysis, showing pronounced epitope specificity to the encephalitogenic MBP peptide 81-103. This peptide retained its substrate properties when flanked with two fluorescent proteins, providing a novel fluorescent resonance energy transfer approach for MS studies. Thus, anti-MBP autoantibody-mediated, epitope-specific binding and cleavage may be regarded as a specific characteristic of MS compared with OND and healthy donors and may serve as an additional biomarker of disease progression.

    ID:722
  19. Reshetnyak A.V., Armentano M.F., Ponomarenko N.A., Vizzuso D., Durova O.M., Ziganshin R., Serebryakova M., Govorun V., Gololobov G., Morse H.C. 3rd, Friboulet A., Makker S.P., Gabibov A.G., Tramontano A. (2007). Routes to covalent catalysis by reactive selection for nascent protein nucleophiles. J. Am. Chem. Soc. 129 (51), 16175–82 [+]

    Reactivity-based selection strategies have been used to enrich combinatorial libraries for encoded biocatalysts having revised substrate specificity or altered catalytic activity. This approach can also assist in artificial evolution of enzyme catalysis from protein templates without bias for predefined catalytic sites. The prevalence of covalent intermediates in enzymatic mechanisms suggests the universal utility of the covalent complex as the basis for selection. Covalent selection by phosphonate ester exchange was applied to a phage display library of antibody variable fragments (scFv) to sample the scope and mechanism of chemical reactivity in a naive molecular library. Selected scFv segregated into structurally related covalent and noncovalent binders. Clones that reacted covalently utilized tyrosine residues exclusively as the nucleophile. Two motifs were identified by structural analysis, recruiting distinct Tyr residues of the light chain. Most clones employed Tyr32 in CDR-L1, whereas a unique clone (A.17) reacted at Tyr36 in FR-L2. Enhanced phosphonylation kinetics and modest amidase activity of A.17 suggested a primitive catalytic site. Covalent selection may thus provide access to protein molecules that approximate an early apparatus for covalent catalysis.

    ID:134
  20. Ponomarenko N.A., Durova O.M., Vorobiev I.I., Belogurov A.A. Jr, Telegin G.B., Suchkov S.V., Misikov V.K., Morse H.C. 3rd, Gabibov A.G. (2006). Catalytic activity of autoantibodies toward myelin basic protein correlates with the scores on the multiple sclerosis expanded disability status scale. Immunol. Lett. 103 (1), 45–50 [+]

    Autoantibodies toward myelin basic protein (MBP) evidently emerge in sera and cerebrospinal fluid of the patients with multiple sclerosis (MS), as well as in a MS rodent model, i.e., experimental autoimmune encephalomyelitis (EAE). The studies of the last two decades have unveiled somewhat controversial data on the diagnostic applicability of anti-MBP autoantibodies as a disease' marker. Here, we present the results of new functional analysis of the anti-MBP autoantibodies isolated from MS (in patients) and EAE (in mice) sera, based on their proteolytic activity against the targeted autoantigen. The activity was shown to be the intrinsic property of the IgG molecule. No activity was found in the sera-derived antibody fraction of healthy donors and control mice. Sera of 24 patients with clinically proven MS at different stages of the disease, and 20 healthy controls were screened for the anti-MBP antibody-mediated proteolytic activity. The activity correlated with the scores on the MS expanded disability status scale (EDSS) (r(2)=0.85, P<0.001). Thus, the anti-MBP autoantibody-mediated proteolysis may be regarded as an additional marker of the disease progression.

    ID:723
  21. Ponomarenko N.A., Durova O.M., Vorobiev I.I., Belogurov A.A. Jr, Kurkova I.N., Petrenko A.G., Telegin G.B., Suchkov S.V., Kiselev S.L., Lagarkova M.A., Govorun V.M., Serebryakova M.V., Avalle B., Tornatore P., Karavanov A., Morse H.C. 3rd, Thomas D., Friboulet A., Gabibov A.G. (2006). Autoantibodies to myelin basic protein catalyze site-specific degradation of their antigen. Proc. Natl. Acad. Sci. U.S.A. 103 (2), 281–6 [+]

    Autoantibody-mediated tissue destruction is among the main features of organ-specific autoimmunity. This report describes "an antibody enzyme" (abzyme) contribution to the site-specific degradation of a neural antigen. We detected proteolytic activity toward myelin basic protein (MBP) in the fraction of antibodies purified from the sera of humans with multiple sclerosis (MS) and mice with induced experimental allergic encephalomyelitis. Chromatography and zymography data demonstrated that the proteolytic activity of this preparation was exclusively associated with the antibodies. No activity was found in the IgG fraction of healthy donors. The human and murine abzymes efficiently cleaved MBP but not other protein substrates tested. The sites of MBP cleavage determined by mass spectrometry were localized within immunodominant regions of MBP. The abzymes could also cleave recombinant substrates containing encephalytogenic MBP(85-101) peptide. An established MS therapeutic Copaxone appeared to be a specific abzyme inhibitor. Thus, the discovered epitope-specific antibody-mediated degradation of MBP suggests a mechanistic explanation of the slow development of neurodegeneration associated with MS.

    ID:132
  22. Ponomarenko N.A., Vorobiev I.I., Alexandrova E.S., Reshetnyak A.V., Telegin G.B., Khaidukov S.V., Avalle B., Karavanov A., Morse H.C. 3rd, Thomas D., Friboulet A., Gabibov A.G. (2006). Induction of a protein-targeted catalytic response in autoimmune prone mice: antibody-mediated cleavage of HIV-1 glycoprotein GP120. Biochemistry 45 (1), 324–30 [+]

    We have induced a polyclonal IgG that degrades the HIV-1 surface antigen, glycoprotein gp120, by taking advantage of the susceptibility of SJL mice to a peptide-induced autoimmune disorder, experimental autoimmune encephalomyelitis (EAE). Specific pathogen-free SJL mice were immunized with structural fragments of gp120, fused in-frame with encephalitogenic peptide MBP(85-101). It has resulted in a pronounced disease-associated immune response against antigens. A dramatic increase of gp120 degradation level by purified polyclonal IgG from immunized versus nonimmunized mice has been demonstrated by a newly developed fluorescence-based assay. This activity was inhibited by anti-mouse immunoglobulin antibodies as well as by Ser- and His-reactive covalent inhibitors. A dominant proteolysis site in recombinant gp120 incubated with purified polyclonal IgG from immunized mice was shown by SDS-PAGE. The SELDI-based mass spectrometry revealed that these antibodies exhibited significant specificity toward the Pro484-Leu485 peptide bond. The sequence surrounding this site is present in nearly half of the HIV-I variants. This novel strategy can be generalized for creating a catalytic vaccine against viral pathogens.

    ID:133
  23. Shuster A.M., Gololobov G.V., Kvashuk O.A., Bogomolova A.E., Smirnov I.V., Gabibov A.G. (1992). DNA hydrolyzing autoantibodies. Science 256 (5057), 665–7 [+]

    A DNA-nicking activity was detected in the sera of patients with various autoimmune pathologies and was shown to be a property of autoantibodies. The DNA hydrolyzing activity, which was purified by affinity and high-performance liquid chromatography, corresponded in size to immunoglobulin M (IgM) and IgG and had a positive response to antibodies to human IgG. The DNA hydrolyzing autoantibodies were stable to acid shock and yielded a DNA degradation pattern that was different from that of deoxyribonuclease (DNase) I and blood DNase.

    ID:131

Габибов Александр Габибович

  • Москва, ул. Миклухо-Маклая, 16/10 — На карте
  • ИБХ РАН, корп. 31, комн. 600
  • Тел.: +7(495)727-38-60
  • Эл. почта: gabibov@mx.ibch.ru

The QM-maturation scheme (2016-11-15)

Селекция in vitro антител из широких репертуаров с использованием комбинаторных библиотек является мощным инструментом для поиска специфических центров связывания и катализа. Впервые предложено  применить алгоритмы для виртуального отбора наиболее эффективных иммуноглобулинов, обладающих каталитической функцией. Для этого были применены QM/MM расчеты реакций деградации антигенов, после чего параметры этих реакций были использованы для выработки критериев виртуального скрининга.

проведена вторая фаза клинических испытаний препарата Xemys для лечения рассеянного склероза (2016-11-15)

•Проведена вторая фаза клинических испытаний инкапсулированных  пептидов, фрагментов основного белка миелина для лечения рассеянного склероз Введение этих пептидов инкапсулированных в монозилированные липосомы нормализовало уровень сывороточного TNF-alpha и IL-2 и хемоаттрактантов CCL2 и CCl4 у пациентов с диагнозом рассеянного склероза. Препарат по всей видимости может иметь перспективу использования в случае неудач в применении препаратов первой линии